AI for Science: The Next Big AI Opportunity

AI for Science: The Next Big AI Opportunity

AI's biggest opportunity may not be productivity, but faster discovery. What boards need to know about AI, science, R&D and competitive advantage.

AI’s Next Big Opportunity Is Not Productivity. It Is Discovery.

200 million.

That is roughly how many protein structure predictions AlphaFold has made available to researchers. A scientific problem that had consumed enormous amounts of experimental time was suddenly attacked at computational scale.

That number matters far beyond biology.

For most of the past few years, the business conversation around artificial intelligence has been dominated by productivity: write the report faster, automate customer service, reduce coding effort, remove administrative work.

All useful.

I also think we may eventually look back and conclude that this was the least interesting part of the AI revolution.

After three decades around enterprise technology decisions, I have seen the same pattern repeatedly. A new technology arrives, and management instinctively asks the safest question first: 

What existing process can this make cheaper?

The more valuable question is usually different:

What becomes possible now that was previously too slow, too expensive, or too complex to attempt?

That is why the movement of talent and capital toward AI-assisted scientific discovery deserves boardroom attention.

The conventional wisdom says that the next stage of AI is about smarter assistants and autonomous agents doing more knowledge work.

I disagree.

The much bigger prize may be systems capable of shortening the cycle between a question and a verified answer.

That is not merely productivity.

That is discovery as an economic capability.

The AI Race Is Moving Beyond Productivity

The signals are becoming difficult to ignore.

In August 2026, Google announced that long-time technology leaders Jeff Dean and Sanjay Ghemawat were leaving to create an independent public benefit corporation focused on accelerating discoveries in machine learning, science and engineering. Alphabet is supporting the venture as a founding investor and Google Cloud partner. Other prominent researchers are pursuing similar AI-for-science efforts.

The important part of that story is not executive movement.

It is where some of the industry's most valuable talent believes the next frontier lies.

We are seeing the pieces converge:

• increasingly capable reasoning systems,

• enormous computing capacity,

• robotic and automated laboratories,

• specialised scientific datasets,

• experienced researchers willing to build companies around the problem,

• and investors willing to fund long-duration bets.

Periodic Labs, for example, is building around automated experimentation and scientific discovery. Lila Sciences has pursued a similar model combining AI with automated laboratories. The common idea is significant: generate knowledge by allowing computational systems to participate directly in the experimental cycle, rather than merely analyse information after humans produce it.

This is the shift boards should pay attention to.

The first enterprise AI wave asks:

How can AI make our current work faster?

The next may ask:

How can AI increase the rate at which our organisation learns something competitors do not know?

Those are very different investment propositions.

Scientific Discovery Is Fundamentally a Cycle-Time Problem

Strip away the complexity and much of science follows a loop:

Observe. Form a hypothesis. Design an experiment. Run it. Analyse the result. Revise the hypothesis. Repeat.

The constraint has traditionally been that parts of this loop are expensive, sequential and dependent on scarce expert time.

AI potentially changes several parts simultaneously.

A system can search literature.

It can identify relationships across enormous datasets.

It can propose hypotheses.

It can suggest experimental designs.

It can analyse results and determine what should be tested next.

Increasingly, those recommendations can be connected to automated experimental systems.

Recent research illustrates how quickly that boundary is moving. A 2026 Nature paper described Co-Scientist, a system intended to support hypothesis generation, identify unexpected connections and assist with experimental planning. Another Nature paper described Robin, a multi-agent system automating hypothesis generation and data analysis in experimental biology.

More importantly, the loop is beginning to touch the physical world.

OpenAI reported an experiment in which GPT-5-driven iterations improved the efficiency of a molecular cloning protocol by 79 times. In another collaboration involving an AI-driven autonomous laboratory, it reported a 40 percent reduction in cell-free protein production cost. These are specific experimental results, not proof that AI can autonomously transform biology, but they demonstrate the economic variable boards should watch: how rapidly the cost and time per validated experiment can fall.

That is where the disruption begins.

Stop Measuring AI by How Many Hours It Saves

Most enterprise AI business cases still rely heavily on labour efficiency.

Hours saved.

Headcount avoided.

Tickets resolved.

Code produced.

Documents generated.

Those metrics make sense because they are measurable.

But they can also trap management into using a transformational technology to optimise yesterday's operating model.

In science-intensive industries, the more valuable metric may be:

Cost per validated learning cycle.

Consider the difference.

If AI allows a pharmaceutical research team to prepare reports 30 percent faster, that is productivity.

If AI allows the organisation to test ten times as many plausible hypotheses against experimental evidence using the same capital base, that is strategic leverage.

If a materials company can explore thousands of candidate compounds while a competitor explores hundreds, the advantage is not primarily administrative efficiency.

It is learning velocity.

Over time, learning velocity becomes competitive advantage.

The company that conducts more high-quality experiments, learns from failures faster and redirects capital earlier may discover the winning molecule, material, process or design before everyone else.

That is something a board should understand immediately.

The Real Moat Will Be the Discovery Loop

There is another piece of conventional wisdom worth challenging.

Much of today's AI strategy assumes the model itself is the differentiator.

I doubt that remains true for many industries.

Models will improve. Access will broaden. Capabilities that appear extraordinary today will become commercially available tomorrow.

The harder advantage to replicate will be the system surrounding the model.

Imagine two companies using roughly equivalent AI capability.

Company A has decades of clean experimental data, digital access to laboratory equipment, automated testing capacity and disciplined mechanisms for validating results.

Company B has fragmented data, manual processes, isolated research teams and an AI licence.

They do not possess the same capability.

The first company owns a discovery loop.

The second owns software.

That distinction will become increasingly important in pharmaceuticals, chemicals, energy, semiconductors, advanced manufacturing, agriculture and any industry where value depends on discovering better answers before competitors.

The Five-Loop Test for Boards

Before approving a large AI-for-discovery programme, I would want the board and CEO to answer five questions.

1. Are we attacking a valuable bottleneck?

Do not start with the technology.

Start with the constraint.

Where does the company currently lose years, capital or strategic optionality because experimentation is too slow or expensive?

Perhaps it is identifying new compounds.

Perhaps it is testing engineering configurations.

Perhaps it is optimising manufacturing parameters.

Perhaps it is screening drug candidates.

The business case begins with the value of removing that constraint.

If nobody can quantify why learning faster matters, do not fund the AI programme.

2. Do we possess a data advantage?

Generative models trained on publicly available information may produce useful suggestions.

Competitive advantage usually requires something competitors cannot reproduce easily.

That may be proprietary experimental results, historical failures, manufacturing telemetry, clinical observations or decades of specialised engineering knowledge.

This leads to an uncomfortable board question:

Is the company's accumulated knowledge actually usable by machines?

Many enterprises possess valuable data in theory but not in practice.

It sits inside documents, isolated databases, spreadsheets, instruments and the memories of retiring specialists.

The race to organise that knowledge may prove as important as the race to acquire models.

3. Can AI close the experimentation loop?

This is where many strategies will fail.

Producing hypotheses quickly has limited value if experiments still require months to design, approve, schedule and execute.

The critical question is not whether AI can think faster.

It is whether the organisation can test faster.

That may require automated laboratories, simulation environments, robotics, digital twins, better instrumentation or simply redesigned research workflows.

The organisations that connect reasoning with execution will have a much stronger advantage than those treating AI as an advisory layer.

4. How will we independently validate the answer?

Science has one discipline that enterprise AI desperately needs: evidence.

An AI-generated hypothesis is not a discovery.

A predicted molecule is not an approved medicine.

A simulated breakthrough is not a commercial product.

The output becomes valuable only when reality confirms it.

Boards therefore need governance around reproducibility, traceability, human review and independent validation.

This becomes particularly important in medicine, biology and other areas where incorrect conclusions can carry consequences far beyond financial loss.

The faster the discovery engine becomes, the stronger the validation engine must become.

5. Can discovery translate into economic value?

This is the step technology enthusiasts regularly underestimate.

A scientific breakthrough does not automatically create shareholder value.

A drug still needs development, trials, regulatory approval, manufacturing and distribution.

A new material still needs scalable production, customer qualification and economically viable supply chains.

The board should therefore track two loops:

Scientific learning velocity and commercialisation velocity.

Accelerating the first while ignoring the second merely creates a larger backlog of interesting ideas.

Medicine Shows Both the Opportunity and the Limitation

Medicine is where the excitement will probably become greatest.

It is also where expectations require the most discipline.

AI may dramatically compress specific activities involved in understanding proteins, designing molecules, reviewing evidence or choosing experiments.

AlphaFold's database of more than 200 million predicted protein structures is already an extraordinary example of what happens when one research bottleneck becomes computational.

But discovering a promising candidate and safely delivering a medicine to millions of people are very different achievements.

Clinical evidence cannot simply be generated by a language model.

Manufacturing constraints do not disappear.

Regulatory accountability does not disappear.

Human biology does not become predictable because computing gets cheaper.

This is why I am sceptical when people describe AI as replacing scientists.

The more credible opportunity is much more interesting.

AI can potentially allow scientists to investigate more possibilities, discard weak options earlier and spend scarce human judgment on the questions where it matters most.

The aim is not scientist removal.

It is scientist leverage.

What Should CEOs Do Now?

For most companies, the answer is not to build an autonomous laboratory next quarter.

It is to identify where the economics of learning matter.

Ask your R&D leaders:

What experiment takes us six months that should take six weeks?

What hypothesis do we avoid testing because experimentation is too expensive?

Which historical failures contain knowledge we have never systematically captured?

Where does expert scarcity constrain the number of ideas we can evaluate?

What would happen economically if we could increase validated experiments per year by five times?

Those conversations will produce a far more useful AI strategy than another discussion about enterprise chatbot adoption.

The winners may not be the companies spending the most on AI.

They may be the companies that redesign themselves to learn faster than everyone else.

The Next AI Advantage Will Be Measured in Years, Not Tokens

For several years the AI industry has competed on parameters, benchmark scores, context windows and model capability.

Important measures, certainly.

But businesses eventually care about outcomes.

A pharmaceutical company cares whether a therapy reaches patients.

A manufacturer cares whether a new process reduces cost.

An energy company cares whether a new material improves economics.

A board cares whether capital produces durable advantage.

That brings us to the metric I believe will eventually matter most:

How much real-world discovery time did AI remove?

If a problem that once required ten years can reliably be solved in five, enormous value is created.

If five years becomes one, entire industries change.

That is why I believe scientific discovery may become one of AI's most important opportunities.

Not because AI will suddenly become a genius scientist.

Not because laboratories will empty of people.

And not because every scientific problem will yield to more computing.

It matters because we may finally have the ingredients required to attack one of innovation's oldest constraints:

the speed at which we can turn uncertainty into verified knowledge.

For boards, that is the opportunity to watch.

And for companies whose competitive advantage depends on R&D, it may soon become the capability they cannot afford to ignore.

What is the most expensive unanswered question in your industry, and what would change if your organisation could answer it five times faster?

If this is the kind of technology conversation you value, subscribe to TechnologyTrends or add your perspective in the comments.